Literature DB >> 25687508

Using chemo-drugs or irradiation to break immune tolerance and facilitate immunotherapy in solid cancer.

Yawen Zheng1, Yan Dou1, Lili Duan1, Changsheng Cong1, Aiqin Gao1, Qinghua Lai1, Yuping Sun2.   

Abstract

The immunity is dual host-protective and tumor-promoting in cancer development and progression. Many immune suppressive cells and cytokines in microenvironment can prevent cytotoxic T lymphocytes (CTL) and natural killer cells (NK) from killing tumor cells. Chemotherapy drugs and irradiation have been reported helpful in breaking immune tolerance and creating microenvironment for adoptive cell therapy. Low-dose cyclophosphamide or gemcitabine therapy can selectively deplete T regulatory cells (Treg). Paclitaxel can alter cytokine network at the tumor site, and 5-fluorouracil shows a pronounced effect on myeloid-derived suppressor cells (MDSC) depletion. Local tumor irradiation and total body irradiation (TBI) can also affect tumor microenvironment and facilitate immunotherapy. In this review, we summarize the particular effects of these agents and methods on immunomodulation, as well as their potential values in immunotherapy. The combination with immunotherapy represents a novel therapeutic strategy.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chemo-drug; Immune tolerance; Immunotherapy; Irradiation; Low-dose

Mesh:

Substances:

Year:  2015        PMID: 25687508     DOI: 10.1016/j.cellimm.2015.02.003

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  33 in total

1.  Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer.

Authors:  Fangxuan Li; Yang Zhao; Lijuan Wei; Shixia Li; Juntian Liu
Journal:  Cancer Biol Ther       Date:  2018-05-08       Impact factor: 4.742

Review 2.  Chemically enhanced radiotherapy: visions for the future.

Authors:  Swaroop Revannasiddaiah; Sridhar P Susheela
Journal:  Ann Transl Med       Date:  2016-02

Review 3.  CAR T-cell therapy for pancreatic cancer.

Authors:  Carl J DeSelm; Zachary E Tano; Anna M Varghese; Prasad S Adusumilli
Journal:  J Surg Oncol       Date:  2017-03-27       Impact factor: 3.454

4.  Matrix Metalloproteinase 8: Could it Benefit the CAR-T Cell Therapy of Solid Tumors?- a- Commentary on Therapeutic Potential.

Authors:  Alireza Mardomi; Saeid Abediankenari
Journal:  Cancer Microenviron       Date:  2018-03-27

5.  Epstein-Barr virus-targeted therapy in nasopharyngeal carcinoma.

Authors:  Sharon D Stoker; Zlata Novalić; Maarten A Wildeman; Alwin D R Huitema; Sandra A W M Verkuijlen; Hedy Juwana; Astrid E Greijer; I Bing Tan; Jaap M Middeldorp; Jan Paul de Boer
Journal:  J Cancer Res Clin Oncol       Date:  2015-04-29       Impact factor: 4.553

6.  Vitamin E-rich Nanoemulsion Enhances the Antitumor Efficacy of Low-Dose Paclitaxel by Driving Th1 Immune Response.

Authors:  Jun Ye; Wujun Dong; Yanfang Yang; Huazhen Hao; Hengfeng Liao; Bangyuan Wang; Xue Han; Yiqun Jin; Xuejun Xia; Yuling Liu
Journal:  Pharm Res       Date:  2017-03-21       Impact factor: 4.200

7.  Formulation of the bivalent prostate cancer vaccine with surgifoam elicits antigen-specific effector T cells in PSA-transgenic mice.

Authors:  Dev Karan
Journal:  Vaccine       Date:  2017-09-20       Impact factor: 3.641

8.  Older age impacts radiotherapy-related outcomes in soft tissue sarcoma.

Authors:  Noah K Yuen; Chin-Shang Li; Arta M Monjazeb; Dariusz Borys; Richard J Bold; Robert J Canter
Journal:  J Surg Res       Date:  2015-06-16       Impact factor: 2.192

9.  Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment.

Authors:  Andrew Stiff; Prashant Trikha; Robert Wesolowski; Kari Kendra; Vincent Hsu; Sarvani Uppati; Elizabeth McMichael; Megan Duggan; Amanda Campbell; Karen Keller; Ian Landi; Yiming Zhong; Jason Dubovsky; John Harrison Howard; Lianbo Yu; Bonnie Harrington; Matthew Old; Sean Reiff; Thomas Mace; Susheela Tridandapani; Natarajan Muthusamy; Michael A Caligiuri; John C Byrd; William E Carson
Journal:  Cancer Res       Date:  2016-02-15       Impact factor: 12.701

10.  Gemcitabine Activates Natural Killer Cells to Attenuate Pancreatic Cancer Recurrence.

Authors:  David W Dawson; Martin E Fernandez-Zapico
Journal:  Gastroenterology       Date:  2016-06-29       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.